[go: up one dir, main page]

PE20010303A1 - NEW PREPARATION AND FORM OF PRESENTATION CONTAINING AN ACTIVE LABILE AGENT IN ACID MEDIUM CONSISTING OF AN INHIBITOR OF THE PROTON PUMP LABIL IN ACID MEDIUM - Google Patents

NEW PREPARATION AND FORM OF PRESENTATION CONTAINING AN ACTIVE LABILE AGENT IN ACID MEDIUM CONSISTING OF AN INHIBITOR OF THE PROTON PUMP LABIL IN ACID MEDIUM

Info

Publication number
PE20010303A1
PE20010303A1 PE2000000565A PE0005652000A PE20010303A1 PE 20010303 A1 PE20010303 A1 PE 20010303A1 PE 2000000565 A PE2000000565 A PE 2000000565A PE 0005652000 A PE0005652000 A PE 0005652000A PE 20010303 A1 PE20010303 A1 PE 20010303A1
Authority
PE
Peru
Prior art keywords
acid medium
labil
inhibitor
presentation
proton pump
Prior art date
Application number
PE2000000565A
Other languages
Spanish (es)
Inventor
Rudolf Linder
Rango Dietrich
Original Assignee
Altana Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=7910295&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20010303(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Altana Pharma Ag filed Critical Altana Pharma Ag
Publication of PE20010303A1 publication Critical patent/PE20010303A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0007—Effervescent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

SE REFIERE A UNA FORMA DE PRESENTACION PARA AGENTES ACTIVOS LABILES EN MEDIO ACIDO QUE COMPRENDE ADYUVANTES FARMACEUTICOS; UNIDADES INDIVIDUALES MULTIPLES DE AGENTE ACTIVO TAL COMO MICROBOLAS CONTENIDO UN INHIBIDOR DE LAS BOMBAS DE PROTONES LABIL TAL COMO PANTOPRAZOL, CARACTERIZADO PORQUE EL AGENTE ACTIVO SE ENCUENTRA EN UNA MATRIZ CONSTITUIDA POR UNA MEZCLA QUE CONTIENE AL MENOS i)UN ALCOHOL GRASO; ii)UN TRIGLICERIDO; iii)UN ESTER DE ACIDO GRASO Y AL MENOS UNA PARAFINA SOLIDA; TAMBIEN PUEDE COMPRENDER LA FORMA DE PRESENTACION ADYUVANTES ADICIONALES TAL COMO POLIMEROS (POVIDONA, COPOLIMERO VINILPIRROLIDONA ACETATO DE VINILO, POLIACETATO DE VINILO, ETER DE CELULOSA, ENTRE OTROS), ESTEROLES (ERGOSTERINA, ESTIGMASTEROL, SITOSTEROL, ENTRE OTROS), COMPUESTOS BASICOS (CARBONATO DE AMONIO, CARBONATO DE SODIO, MEGLUMINA, TRIETILAMINA, ENTRE OTROS). TAMBIEN SE REFIERE A UN PROCEDIMIENTO PARA LA PREPARACIONREFERS TO A FORM OF PRESENTATION FOR LABIL ACTIVE AGENTS IN ACID MEDIUM, INCLUDING PHARMACEUTICAL ADJUVANTS; MULTIPLE INDIVIDUAL UNITS OF ACTIVE AGENT SUCH AS MICROBALLS CONTAINED AN INHIBITOR OF LABIL PROTON PUMPS SUCH AS PANTOPRAZOLE, CHARACTERIZED BECAUSE THE ACTIVE AGENT IS FOUND IN A MATRIX CONSTITUTED BY A MIXTURE i) AOH LESS; ii) A TRIGLYCERIDE; iii) A FATTY ACID ESTER AND AT LEAST ONE SOLID PARAFFIN; IT MAY ALSO INCLUDE THE PRESENTATION FORM OF ADDITIONAL ADJUVANTS SUCH AS POLYMERS (POVIDONE, VINYLPYRROLIDONE COPOLYMER VINYLPYRROLIDONE ACETATE, VINYL POLYACETATE, CELLULOSE ETHER, BETWEEN OTHERS), STEROLOSTEROLS, STIMOSTEROLS (ERGITOSTEROL BASES) AMMONIUM, SODIUM CARBONATE, MEGLUMINE, TRIETILAMINE, AMONG OTHERS). ALSO REFERS TO A PROCEDURE FOR THE PREPARATION

PE2000000565A 1999-06-07 2000-06-07 NEW PREPARATION AND FORM OF PRESENTATION CONTAINING AN ACTIVE LABILE AGENT IN ACID MEDIUM CONSISTING OF AN INHIBITOR OF THE PROTON PUMP LABIL IN ACID MEDIUM PE20010303A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19925710A DE19925710C2 (en) 1999-06-07 1999-06-07 New preparation and dosage form containing an acid labile proton pump inhibitor

Publications (1)

Publication Number Publication Date
PE20010303A1 true PE20010303A1 (en) 2001-03-09

Family

ID=7910295

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2000000565A PE20010303A1 (en) 1999-06-07 2000-06-07 NEW PREPARATION AND FORM OF PRESENTATION CONTAINING AN ACTIVE LABILE AGENT IN ACID MEDIUM CONSISTING OF AN INHIBITOR OF THE PROTON PUMP LABIL IN ACID MEDIUM

Country Status (6)

Country Link
AR (1) AR024310A1 (en)
CO (1) CO5160296A1 (en)
DE (1) DE19925710C2 (en)
MY (1) MY138975A (en)
PE (1) PE20010303A1 (en)
TW (1) TWI255720B (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA80393C2 (en) 2000-12-07 2007-09-25 Алтана Фарма Аг Pharmaceutical preparation comprising an pde inhibitor dispersed on a matrix
DE10061137B4 (en) * 2000-12-07 2016-10-06 Takeda Gmbh New pharmaceutical preparation
JP4241041B2 (en) * 2000-12-07 2009-03-18 ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング Paste-form pharmaceutical product containing an acid-degradable active ingredient
DE10061136C1 (en) * 2000-12-07 2002-10-24 Byk Gulden Lomberg Chem Fab Stable, rapidly disintegrating tablets containing proton pump inhibitors, useful for treating elevated gastric secretion, comprising multiple drug units and auxiliaries including basic filler
CA2430829C (en) * 2000-12-07 2010-06-22 Altana Pharma Ag Rapidly disintegrating tablet comprising an acid-labile active ingredient
DE10061135C1 (en) * 2000-12-07 2002-11-07 Byk Gulden Lomberg Chem Fab Stable gel preparation for oral administration of acid-labile drug, especially proton pump inhibitor, comprises multiple drug units dispersed in gel base
DE10061138C1 (en) * 2000-12-07 2002-08-14 Byk Gulden Lomberg Chem Fab Pharmaceutical preparation in the form of a juice containing an acid-labile active ingredient
CN100528232C (en) 2000-12-07 2009-08-19 尼科梅德有限责任公司 Pharmaceutical preparation in form of suspension comprising acid-labile active ingredient
SE0101379D0 (en) 2001-04-18 2001-04-18 Diabact Ab Composition that inhibits gastric acid secretion
MXPA04002992A (en) 2001-09-28 2005-06-20 Johnson & Johnson Edible composition and dosage form comprising an edible shell.
MY140561A (en) 2002-02-20 2009-12-31 Nycomed Gmbh Dosage form containing pde 4 inhibitor as active ingredient
JP5148813B2 (en) * 2002-07-03 2013-02-20 タケダ ファーマシューティカルズ ユー．エス．エー． インコーポレイティド Liquid dosage form of proton pump inhibitor
DE10244129B4 (en) * 2002-09-23 2006-04-20 Iongate Biosciences Gmbh H + -K + -ATPase assay
SE0203065D0 (en) 2002-10-16 2002-10-16 Diabact Ab Gastric acid secretion inhibiting composition
PL1606261T3 (en) 2003-03-10 2010-04-30 Astrazeneca Ab Novel process for the preparation of roflumilast
TW200503783A (en) * 2003-04-11 2005-02-01 Altana Pharma Ag Oral pharmaceutical preparation for proton pump antagonists
WO2006097456A1 (en) 2005-03-16 2006-09-21 Nycomed Gmbh Taste masked dosage form containing roflumilast

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2725924C3 (en) * 1977-06-08 1980-11-06 Hobeg Hochtemperaturreaktor-Brennelement Gmbh, 6450 Hanau Process for the production of spherical particles from low-melting organic substances
DE3524572A1 (en) * 1985-07-10 1987-01-15 Thomae Gmbh Dr K SOLID PHARMACEUTICAL FORMS FOR PERORAL USE CONTAINING 9-DEOXO-11-DEOXY-9,11- (IMINO (2- (2-METHOXYETHOXY) ETHYLIDEN) -OXY) - (9S) -ERYTHROMYCIN AND METHOD FOR THE PRODUCTION THEREOF
JP2681373B2 (en) * 1988-07-18 1997-11-26 塩野義製薬株式会社 Method for manufacturing sustained-release preparation

Also Published As

Publication number Publication date
TWI255720B (en) 2006-06-01
MY138975A (en) 2009-08-28
AR024310A1 (en) 2002-09-25
DE19925710A1 (en) 2000-12-14
DE19925710C2 (en) 2002-10-10
CO5160296A1 (en) 2002-05-30

Similar Documents

Publication Publication Date Title
PE20010303A1 (en) NEW PREPARATION AND FORM OF PRESENTATION CONTAINING AN ACTIVE LABILE AGENT IN ACID MEDIUM CONSISTING OF AN INHIBITOR OF THE PROTON PUMP LABIL IN ACID MEDIUM
ES2542728T3 (en) Pharmaceutical compositions that have desirable bioavailability
UA74339C2 (en) Dosage form of proton pump inhibitor representing individual matrix-included units and method for its manufacture
RU2005110945A (en) CAPSULES CONTAINING AQUEOUS FILLING COMPOSITIONS STABILIZED BY A CYCLODEXTRINE DERIVATIVE
ES2625145T3 (en) Topical application and formulation of erythropoietin to heal skin wounds
AR032497A1 (en) ANTIMICROBIAL CLEANER ACID FOR HARD SURFACES
ATE331517T1 (en) PHARMACEUTICAL COMPOSITIONS
ES2155043B1 (en) PHARMACEUTICAL COMPOSITIONS UNDERSTANDING ACID PIRIMIDIN-5-IL (3R, 5S) -3,5-DIHIDROXIHEPT-6-ENOICO OR A SALT OF HER, ITS STABILIZATION WITH TRIBASIC PHOSPHATE SALT AND ITS PREPARATION.
PE3296A1 (en) ORAL COMPOSITION CONTAINING A MUCOADHESIVE
ES2190819T3 (en) PROCEDURE FOR PREPARATION OF NOVEL GALENIC FORMULATIONS CONTAINING PHENOBRINATE, GALENIC FORMULATIONS AS WELL OBTAINED AND THEIR APPLICATIONS.
PE20081365A1 (en) TOPICAL FORMULATIONS FOR LOCAL ADMINISTRATION CONTAINING INDOXACARB
PT2116243E (en) Gel composition for treating mycosis
AR038681A1 (en) ORAL FORMULATION OF SOLID SOLUTION OF A POVERLY SOLUBLE ACTIVE SUBSTANCE IN WATER
PE20041024A1 (en) CONTROLLED RELEASE SYSTEM
BR0007360A (en) Controlled release composition
MY143793A (en) Non-tabletted, chewable, individually dosed administration forms
CO5380014A1 (en) PHARMACEUTICAL FORMULATION FOR ORAL OR TOPIC ADMINISTRATION OF HYDROPHOBIC COMPOUNDS THAT DOES NOT FRAME EMULSION
WO2022039850A1 (en) Tofacitinib-containing anhydrous elastomer-based gel formulations
NO820319L (en) ANTIMYCOTIC AGENTS IN THE FORM OF PRINCIPLES AND WITH HIGH-EFFICIENT SUBSTANCES
CA2466726A1 (en) Preparation composition containing acid-unstable physiologically active compound and process for producing same
PE20040545A1 (en) PARASITICIDE FORMULATIONS INCLUDING BENZOIMIDAZOLES OR SALICILANILIDES IN COMBINATION WITH MACROCICLIC LACTONES
ES2530874T3 (en) Short-term deposit formulations
PE17897A1 (en) TRANSDERMIC FORMULATION IN PATCH OF 3- (4-BUTILTIO) -1,2,5-TIADIAZOL-3-IL) -1-AZABICICLO (2,2,2) OCTANO
CO5160318A1 (en) PRECURSORY COMPOSITION TO PREPARE A DIALYTIC
SE451666B (en) STABLE BENZOYL PEROXIDE COMPOSITION

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed